The renewal comes as Takeda enters the 11th year of a multiyear collaboration with the WFH Humanitarian Aid Program. This latest commitment will bring the company’s total donation to 215 million IUs of factor up until 2030—with 65 million IUs of treatment product coming as part of the new agreement. The products in the new agreement will be used to support not only people with hemophilia, but people who have inhibitors and von Willebrand disease (VWD)—particularly women and girls with bleeding disorders.
“We are honoured to have contributed to improving the lives of thousands of patients for over a decade through this partnership, and we look forward to helping further bridge gaps in treatment access in underserved regions,” said Thomas R. Kreil, Vice President, Global Pathogen Safety, Takeda. “We remain committed to our shared mission of ensuring equitable care and to our longstanding collaboration with the WFH.”
“This generous, multi-product donation will enable even more people with bleeding disorders to access the treatment they need,” said Cesar Garrido, President of the WFH. “Contributions like this play a crucial role in expanding access to care and advancing our shared vision of Treatment for All. The donation of two products is especially impactful, as it will allow us to have a positive effect on the lives of people with different conditions, such as people with VWD, people with inhibitors, and women and girls with bleeding disorders. We are deeply grateful to Takeda for choosing us to use this donation to improve lives around the world for the members of our community.”
To find out more about the WFH Humanitarian Aid Program, please click here.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.
